Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®)
https://doi.org/10.14412/2074-2711-2011-162
Abstract
Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a broad spectrum of not only movement, but also neuropsychiatry disorders (NPD). The efficiency of dopamine therapy in correcting NPD needs to be clarified.
Objective: to evaluate the impact of therapy with the MAO-B inhibitor rasagiline (Azilect®) on NPD in patients with extended stages of PD.
Subjects and methods. Twenty PD (disease duration 10.2+5.08 years; stage 2.4+0.5) patients with the wearing-of phenomenon were given rasagiline ' mg/day in addition to antiparkinsonian drugs. Following 6 and 24 weeks of therapy, its efficiency was evaluated using the unified PD rating scale, the motor fluctuation rating scale, the Beck depression inventory, the PD fatigue scale, the PD sleep scale, the Epworth sleeping scale, and the PD quality of life scale (PDQ-39).
Results. There were reductions in the severity of nocturnal and morning hypokinesia, daytime off periods, depression, insomnia, overfatigue and improved quality of life. The positive effect of therapy was stable within further 6 follow-up months.
Objective: to evaluate the impact of therapy with the MAO-B inhibitor rasagiline (Azilect®) on NPD in patients with extended stages of PD.
Subjects and methods. Twenty PD (disease duration 10.2+5.08 years; stage 2.4+0.5) patients with the wearing-of phenomenon were given rasagiline ' mg/day in addition to antiparkinsonian drugs. Following 6 and 24 weeks of therapy, its efficiency was evaluated using the unified PD rating scale, the motor fluctuation rating scale, the Beck depression inventory, the PD fatigue scale, the PD sleep scale, the Epworth sleeping scale, and the PD quality of life scale (PDQ-39).
Results. There were reductions in the severity of nocturnal and morning hypokinesia, daytime off periods, depression, insomnia, overfatigue and improved quality of life. The positive effect of therapy was stable within further 6 follow-up months.
About the Author
M. R. Nodel
I.M. Sechenov First Moscow State Medical University
Russian Federation
Department of Nervous Diseases
Russian Federation
Department of Nervous Diseases
References
1. <div><p>Нодель М.Р., Яхно Н.Н. Нервно-психические нарушения болезни Паркинсона. Неврол нейропсихиатр психосом 2009;2:3-8.</p><p>Яхно Н.Н., Захаров В.В., Нодель М.Р. Когнитивные и другие нервно-психические нарушения болезни Паркинсона. В кн.: Болезни движений: медицинские и социальные аспекты. Под ред. Е.И. Гусева, А.Б. Гехт. М., 2010;95-7.</p><p>Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinsons Disease. Mov Dis 2009;24(15):2175-86.</p><p>Barone P., Antonini A., Colosimo C. et al. The PRIAMO study: a multicenter assessment of nonmotot symptoms and their impact on quality of life in Parkinson's disease. Mov Dis 2009;24:1641-49.</p><p>Scaravilli T., Gasparoli E., Rinaldi F. et al. Health related quality of life in Parkinsons disease. J Nourol Neurosurg Psychiat 2003;74(2):163-9.</p><p>Shrag A., Jahanshahi M., Quinn N.P. What contributes to quality life in patients with Parkinsons disease? J Neurol Neurosurg Neuropsych 2000;69:308-12.</p><p>Cole S.A., Woodard J.L., Juncos J.L. et al. Depression and disability in Parkinsons disease. J Neuropsychiat Clin Neurosci 1996;8:20-5.</p><p>Mc Kinlay A., Grace R.C., Dalrymple-Alford J.C. et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinsons disease. Park Relat Dis 2008;14:37-42.</p><p>Lemke M.R. Depressive symptoms in Parkinsons disease. Eur J Neurol 2008;15(Suppl. 1):21-5.</p><p>American Psychiatric Association. Diagnostic and Statistical Manual of mental Disorders, 4th ed. Washington, DCAPA Press 2000.</p><p>Inoue T., Kitagawa M., Tanaka T. et al. Depression and major depressive disorder in patients with Parkinsons disease. Mov Dis 2010;25(1):44-9.</p><p>Shrag A., Barone P., Brown R.G. et al. Depression rating scales in Parkinson disease: critique and recommendations. Mov Dis 2007;22:1077-192.</p><p>Нодель М.Р. Утомляемость при болезни Паркинсона. Журн неврол психиатр 2009;9:23-6.</p><p>Schifitto G., Friedman J.H., Oakes D. et al. Fatigue in levodopa-naive subjects with Parkinsons disease. Neurology 2008;71:481-5.</p><p>Brown R.G., Dittner A., Findley L. et al. The Parkinson fatigue scale. Park Relat Dis 2005;11:49-55.</p><p>Garber C.E., Friedman J.H. Effects of fatigue on physical activity and function in patients with Parkinsons disease. Neurology 2003;60(7):119-24.</p><p>Comella C. Sleep disorders in Parkinsons disease: an overview. Mov Dis 2007;22(Suppl. 17):367-73.</p><p>Factor S.A., McAlarney T., Sanchez-Ramos J.R. et al. Sleep disorders and sleep effect in Parkinson's disease. Mov Dis 1990;5:280-5.</p><p>Kumar S., Bhatia M., Behari M. Sleep disorders in Parkinson's disease. Mov Dis 2002;17:775-81.</p><p>Нодель М.Р., Русакова И.М., Яхно Н.Н.. Клиническая оценка нарушений сна и бодрствования при болезни Паркинсона. Неврол журн 2010;2:19-25.</p><p>Chaudhuri K.R., Pal S., Di Marco A. et al. The sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinsons disease. J Nourol Neurosurg Psychiat 2002;73:629-35.</p><p>Chaudhuri K.R., Schapira A.H.V. Nonmotor symptoms of Parkinsons disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74.</p><p>Malhi G.S., Berk M. Does dopamine dysfunction drive depression? Acta Psychiatr Scand Suppl 2007;433:116-24.</p><p>Youdim M.B.H., Gross A., Finberg J.P.M. Rasagiline, a selective and potent inhibitors of of monoamine oxidase B. Br J Pharmacol 2001;132:500-6.</p><p>Eichhorn T.E., Schrag A., Trenkwalder C. et al. Effectiveness of slow release L-DOPA/ benserazide in treatment of end-of-dose akinesia in Parkinson disease. Nevrvenarzt 1995;66(12):933-41.</p><p>Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.</p><p>Левин О.С. Применение нового ингибитора МАО-В - разагилина для лечения моторных флюктуаций при болезни Паркинсона. Журн неврол и психиатр 2008;108:91-6.</p><p>Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8.</p><p>Rascol O., Brooks D.J., Melamed E. et al. and LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations. Lancet 2005;18:94-54.</p><p>Poewe W., Hauser R., Lang A.E. Rasagiline 1 mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson's disease: assessment with the revised MDS-UPDRS. Abstracts of the Movement Disorders Societies Thirteenth International Congress of Parkinson's disease and movement disorders. June 7-11, 2009(Suppl. 1):272-3.</p><p>Muller T., Klasser M., Rieke J. et al. Effect of rasagiline on sleep disturbances and fatigue patients with Parkinsons disease: a pilot study. Abstracts of the 6th International congress on mental dysfunctions and other non-motor features in Parkinsons disease. October 16-19, 2008, Dresden, Germany;170 р.</p><p>Miyasaki J.M., Shannon K., Voon V. et al. Practice parameter :evaluation and treatment of depression, psychosis and dementia in Parkinsons disease (an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.</p></div><br />
Review
For citations:
Nodel M.R. Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®). Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):24-29. (In Russ.) https://doi.org/10.14412/2074-2711-2011-162
Views: 949
Email this article 